银屑病关节炎中的生物制剂转换:真实世界数据与关键风险因素分析
基于以色列Clalit健康服务数据库2005-2023年的回顾性队列研究,纳入9607例银屑病关节炎患者,其中3851例启动bDMARDs,1848例(48%)至少转换一次治疗。抗TNF为首选一线,首次转换以抗IL17为主;女性、肥胖、吸烟和低社会经济地位与转换机制独立相关。
要点
- 3851例启动bDMARDs的银屑病关节炎患者中1848例(48%)至少转换一次治疗。
- 抗TNF为主导一线选择,首次转换以抗IL17为主,后续常转回抗TNF或换用抗IL23/JAK抑制剂。
- 女性、肥胖、吸烟和低社会经济地位与转换机制独立相关。
核心结论
- 跨类别生物制剂转换在银屑病关节炎管理中常见(48%),并受患者人口学特征和合并症影响。
- 尽管治疗选择增加,转换模式在不同时间段保持一致。
研究设计与样本
- 回顾性队列研究,利用Clalit健康服务数据库(2005-2023年),涵盖以色列9607例银屑病关节炎患者。
- 追踪启动bDMARDs的患者治疗转换情况,提取临床、人口学和社会经济变量,比较转换者与非转换者特征。
- 转换模式按转换次数和研究时段(2005-2014年、2015-2023年)分层分析。
主要发现
- 3851例启动bDMARDs的患者中,1848例(48%)至少转换一次治疗。
- 抗TNF治疗为主导一线选择,但首次转换至抗IL17治疗在单次转换和多次转换场景中均变得普遍。
- 后续转换常涉及转回抗TNF或过渡至其他作用机制,如抗IL23或JAK抑制剂。
- 转换模式在研究时段间保持一致。
- 转换者更可能为女性(56.5% vs 50.6%,p < 0.001)、肥胖(28.1% vs 22.6%,p < 0.001)、吸烟(41.6% vs 37.1%,p = 0.005)和低社会经济背景(34.1% vs 31.4%,p = 0.04)。
关键数值与推荐
- 多变量分析中,女性、肥胖、吸烟和低社会经济地位均与转换作用机制独立相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriatic arthritis (PsA) is a chronic, heterogeneous inflammatory condition requiring personalized treatment strategies. Biologic therapy switching reflects the disease's dynamic nature and aims to optimize disease control while balancing efficacy, safety, and patient-specific factors. OBJECTIVE: To analyze real-world switching patterns of biologic disease-modifying antirheumatic drugs (bDMARDs) in PsA patients, identify associated risk factors, and provide insights into predictors of mode-of-action switching. METHODS: This retrospective cohort study utilized the Clalit Health Services database (2005-2023), encompassing 9607 PsA patients in Israel. Patients initiating bDMARDs were tracked for therapy switches. Clinical, demographic, and socioeconomic variables were extracted, and statistical analyses compared characteristics between switchers and non-switchers. Patterns of switching were stratified by the number of switches and study periods (2005-2014, 2015-2023). RESULTS: Among 3851 patients initiating bDMARDs, 1848 (48 %) switched therapy at least once. Anti-TNF therapy was the dominant first-line choice, but switching to anti-IL17 therapy became prevalent as the first switch in both single-switch and multi-switch scenarios. Subsequent switches often involved cycling back to anti-TNF or transitioning to other modes of action, such as anti-IL23 or JAK inhibitors. Switching patterns remained consistent across study periods. Switchers were more likely to be female (56.5 vs. 50.6 %, p < 0.001), obese (28.1 vs. 22.6 %, p < 0.001), smokers (41.6 vs. 37.1 %, p = 0.005), and from lower socioeconomic backgrounds (34.1 vs 31.4 %, p = 0.04). These factors were all independently associated with switching in mechanism of action on multivariate analysis. CONCLUSION: Cross class biologic switching is common in PsA management (48 %) and influenced by patient demographics and comorbidities. Switching patterns were consistent across time periods despite expanding therapeutic options.
引用
- Haddad A, Stein N, Feldhamer I, et al. Biologic switching in psoriatic arthritis: Insights from real-world data and key risk factors. Semin Arthritis Rheum. 2025. PMID: 40267668. doi:10.1016/j.semarthrit.2025.152737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。